BioAtla Inc.

09/16/2024 | Press release | Distributed by Public on 09/16/2024 06:32

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.